Skip to content

Ultrasound guided treatment for heart failure

VExUS and Lung ultrasound Guided Management of Acute Heart Failure: A Randomised Control Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052327
Enrollment
500
Registered
2023-05-04
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I509- Heart failure, unspecified

Interventions

Intervention1: VExUS group: Patients in this arm will receive VExUS scoring and lung ultrasoundâ??targeted diuretic therapy. Diuretic therapy will be provided until decongestion is achieved. Decon

Sponsors

Narayana Hrudayalya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Getting admited with a diagnosis of acute heart failure [defined as recent worsening of shortness of breath or oxygen saturation (SpO2) < 90% on room air or orthopnea/paroxysmal nocturnal dypnea (PND) along with an increase in NT proBNP]

Exclusion criteria

Exclusion criteria: 1.Need for intubation (or already intubated). 2.Signs or symptoms or markers of hypoperfusion: cold extremities, altered mentation, confusion, oliguria, Lactate > 2 mmol/L. 3.Persistent hypotension (SBP 4.Requirement of two or more vasoactive agents to maintain blood pressure. 5.Requirement for invasive cardiac output monitoring. 6.Requirement for Mechanical Circulatory Support. 7.Heart rate 8.Any associated non-cardiac condition requiring critical care admission. 9.Pulmonary arterial systolic pressure > 55mm/hg by bedside 2d-echocardiography 10.Patients with comfort care directives. 11.Suspected sepsis 12.Pregnancy 13.Liver cirrhosis 14.Severe ascites (Grade 3 Ascites defined as Large or gross ascites with marked abdominal distension)

Design outcomes

Primary

MeasureTime frame
RehospitalizationTimepoint: 90 days

Secondary

MeasureTime frame
Length of stay in hospitalTimepoint: At discharge;Major adverse kidney event (MAKE)Timepoint: 90 days;MortalityTimepoint: 90 days;New onset organ failureTimepoint: In hospital

Countries

India

Contacts

Public ContactDr Vimal Bhardwaj

Narayana Hrudayalaya

vmlbhardwaj@yahoo.co.in9686124830

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026